ストックスクリーナーアプリを入手
0.00
100.00%
-41.03
アフターアワーズ：
41.06
41.06
+
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Apellis Pharmaceuticals, Inc. (APLS) tops Q1 earnings and revenue estimates - MSN
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
ViaSat, Innovative Solutions & Support, and Apellis Pharmaceuticals Lead Stock Performance - Markets Mojo
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - FinancialContent
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS Suspended by Cantor Fitzgerald -- Rating Remains Neutral - GuruFocus
Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals - BioPharm International
Biogen upgraded to Hold after Apellis acquisition boosts prospects despite challenges. - Pluang
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity (BIIB) - Seeking Alpha
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins - TechStock²
Deep Track (APLS) reports 4.53M shares, a 3.55% stake - Stock Titan
RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS) - Stock Titan
Biogen completes $5.3B Apellis Pharmaceuticals acquisition - Yahoo Finance
Biogen Completes Acquisition of Apellis Pharmaceuticals - Sahm
Biogen stock (US09062X1037): $5.3 billion Apellis takeover reshapes growth story - AD HOC NEWS
Biogen Acquires Apellis Pharmaceuticals (APLS) to Enhance Growth Potential - GuruFocus
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Apellis Pharmaceuticals (APLS) CFO equity awards converted in Biogen cash-and-CVR merger - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen–Apellis (NASDAQ: APLS) deal closes with $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) CTO reports equity conversion in Biogen cash and CVR buyout - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen–Apellis (APLS) deal pays $41 cash plus CVRs as executive equity is restructured - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) chief people officer reports cash-out and new stock grants in Biogen merger - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Biogen–Apellis (APLS) deal triggers GC’s cash, CVR and option changes - Stock Titan
Biogen–Apellis (NASDAQ: APLS) merger gives $41 cash plus CVRs to shareholders - Stock Titan
Apellis (NASDAQ: APLS) CMO reports stock and option changes in Biogen cash-plus-CVR buyout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Biogen Inc. (BIIB) Completes Acquisition of Apellis Pharmaceuticals - GuruFocus
Biogen (APLS counterparty) closes Apellis tender offer and merger with cash and CVR deal - Stock Titan
Biogen stock (US09062X1037): closes $5.3B Apellis deal - AD HOC NEWS
Why Is Biogen Stock Falling Thursday? - Benzinga
Biogen Completes Acquisition of Apellis Pharmaceuticals, Expanding Portfolio with EMPAVELI and SYFOVRE for Growth in Nephrology and Ophthalmology 1 - Minichart
Apellis Pharmaceuticals Announces Merger With Biogen, Delisting from Nasdaq, and Convertible Notes Repurchase/Conversion Options - Minichart
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over - TechStock²
Biogen completes $5.3 billion acquisition of Apellis Pharmaceuticals By Investing.com - Investing.com Canada
Apellis Pharmaceuticals (NASDAQ: APLS) withdraws Common Stock from Nasdaq - Stock Titan
Biogen Completes Apellis Acquisition to Strengthen Growth - TipRanks
Apellis Completes Biogen Merger and Goes Private - TipRanks
Biogen completes $5.3 billion acquisition of Apellis Pharmaceuticals - Investing.com
Apellis Finalizes Biogen Deal With CVR Payouts Up to $4; Amends Notes, Retires Credit Facility - TradingView
Biogen (APLS) closes Apellis buyout at $41 per share plus CVRs and delists stock - Stock Titan
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):